logo
Goodbye Skype: Microsofts Video-Calling Platform To Retire On May 5; What Will Happen To Current Subscribers?

Goodbye Skype: Microsofts Video-Calling Platform To Retire On May 5; What Will Happen To Current Subscribers?

India.com02-05-2025

Microsoft Skype Shutting Down: Microsoft has announced that it will shut down its video-calling platform, Skype, on May 5 — just a few days from now. The company believes it no longer needs both Skype, the video-calling platform that made headlines in the early 2000s, and Teams in its business plans. This move is a part of the company's broader strategy to consolidate its communication platforms and focus on Microsoft Teams.
However, tech giant Microsoft did not make the decision to shut down Skype overnight and its update was first announced earlier this year. People have got enough time to make the transition from Skype to Teams.
Skype Launch Date
The video platform was launched in 2003 by Danish software developer Janus Friis and Swedish developer Niklas Zennstrom. Skype was among the most popular video-calling platforms.
Skype Features: What Will Happen To Current Subscribers
This change will affect both free and paid Skype users, but not Skype for Business. Microsoft will stop offering paid Skype features to new customers, including Skype Credit and subscriptions for making and receiving domestic and international calls. However, the current subscribers can continue to use their existing credit and active subscriptions until the conclusion of their next renewal cycle.
Skype Users Can Switch To Microsoft Teams
Microsoft says that Skype users will not face any major issues when migrating to Teams, as their existing Skype IDs can be used to log in and easily transfer chats and contacts. However, both platforms have similar features which includes one-on-one and group calls, messaging, and file sharing.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI to buy ART Fertility Clinics for $450 million

Economic Times

time38 minutes ago

  • Economic Times

KKR-backed IVI to buy ART Fertility Clinics for $450 million

Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.

KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI to buy ART Fertility Clinics for $450 million

Time of India

timean hour ago

  • Time of India

KKR-backed IVI to buy ART Fertility Clinics for $450 million

KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.

Xbox full-screen experience on the cards: Microsoft and Asus collab pays off, here's all about it
Xbox full-screen experience on the cards: Microsoft and Asus collab pays off, here's all about it

Mint

time2 hours ago

  • Mint

Xbox full-screen experience on the cards: Microsoft and Asus collab pays off, here's all about it

Two of the world's top tech giants, Microsoft and Asus, joined hands to develop not one, but two Xbox Ally handhelds, which will give users a full-screen experience, along with a new kind of gaming experience. Both of them are part of the Project Kennan initiative that includes thorough development into newer gaming consoles, making them handheld-friendly and reducing the complexity of the Windows platform. One of them is the White ROG Xbox Ally handheld device, which is designed for a standard 720p gaming experience. Then comes the all-powerful black ROG Xbox Ally, which is equipped to support a 900p to 1080p gaming experience. Both of them share a similar screen size and resolution, but the black is more powerful than the white, especially because of its build and gaming support. It also matches the ROG Ally and Ally X, which also have the same 7-inch 1080p screen along with a 120Hz refresh rate. (This story is under development. Please come back for more information.)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store